Found: 8
Select item for more details and to access through your institution.
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 1033, doi. 10.1111/dom.15404
- By:
- Publication type:
- Article
Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1810, doi. 10.1111/dom.14767
- By:
- Publication type:
- Article
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 899, doi. 10.1111/dom.14650
- By:
- Publication type:
- Article
Insulin secretion is a strong predictor for need of insulin therapy in patients with new‐onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 7, p. 1631, doi. 10.1111/dom.14383
- By:
- Publication type:
- Article
Plasma insulin is required for the increase in plasma angiopoietin‐like protein 8 in response to nutrient ingestion.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2023, v. 39, n. 6, p. 1, doi. 10.1002/dmrr.3643
- By:
- Publication type:
- Article
Gastric and urinary bladder pressures correlate with intra-abdominal pressure in patients with morbid obesity.
- Published in:
- Journal of Clinical Monitoring & Computing, 2022, v. 36, n. 4, p. 1021, doi. 10.1007/s10877-021-00728-7
- By:
- Publication type:
- Article
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes.
- Published in:
- Diabetes Care, 2024, v. 47, n. 4, p. 668, doi. 10.2337/dc23-1646
- By:
- Publication type:
- Article
Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients.
- Published in:
- Diabetes Care, 2023, v. 46, n. 5, p. 978, doi. 10.2337/dc22-0885
- By:
- Publication type:
- Article